BrainStorm Announces That It Will Reschedule Its Webcast Audio Conference

This event will be rescheduled for a later date to be announced soon.

We apologize for any inconvenience.

About BrainStorm Cell Therapeutics, Inc.

BrainStorm Cell Therapeutics Inc. is an emerging company developing
adult stem cell therapeutic products, derived from autologous (self)
bone marrow cells, for the treatment of neurodegenerative diseases. The
patent pending technology is based on discoveries made by the scientific
team led by Professor Eldad Melamed, former Head of Neurology at Rabin
Medical Center, and cell biologist Prof. Daniel Offen, Head of the
Neuroscience Laboratory at the Felsenstein Medical Research Center of
Tel-Aviv University. The technology allows for the differentiation of
bone marrow-derived stem cells into functional neurons and astrocytes,
as demonstrated in animal models. The Company holds rights to develop
and commercialize the technology through an exclusive, worldwide
licensing agreement with Ramot at Tel Aviv University Ltd., the
technology transfer company of Tel-Aviv University. The Company's
current focus is on ALS, although its technology has promise for
treating several other diseases including MS, Huntington's disease and
stroke.

Safe Harbor Statement

Statements in this announcement other than historical data and
information constitute "forward-looking statements" and involve risks
and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s
actual results to differ materially from those stated or implied by such
forward-looking statements, including BrainStorm's ability to complete
its equity financing transactions previously disclosed. The potential
risks and uncertainties include, among others, risks associated with
BrainStorm Cell Therapeutics Inc.'s limited operating history, history
of losses and expectation to incur losses for the foreseeable future;
minimal working capital and difficulty raising additional capital,
dependence on its license to Ramot's technology; ability, together with
its licensor, to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to identify,
negotiate and successfully implement strategic partnering relationships;
ability to complete clinical trials successfully and to obtain required
regulatory approvals; competition with companies, some of which have
greater resources and experience in developing and obtaining regulatory
approval for treatments in BrainStorm Cell Therapeutics Inc.'s market;
the limited public trading market for BrainStorm Cell Therapeutics
Inc.'s stock which may never develop into an active market; and other
factors detailed in BrainStorm Cell Therapeutics Inc.'s annual report on
Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K
and other filings with the Securities and Exchange Commission available
at http://www.sec.gov/
or by request to the Company. The Company does not undertake any
obligation to update forward-looking statements made by us.

SOURCE: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. 
Rami Efrati, CEO, +972-3-9236384 
efrati@brainstorm-cell.com

For full details on (BCLI) BCLI. (BCLI) has Short Term PowerRatings at TradingMarkets. Details on (BCLI) Short Term PowerRatings is available at This Link.